Cordis receives FDA clearance for new ADROIT Guiding Catheter

NewsGuard 100/100 Score

Cordis Corporation today announced it has received clearance from the Food and Drug Administration of its latest innovation in guiding catheters: the ADROITTM 6F Guiding Catheter.

"The new ADROITTM Guiding Catheter, allows physicians to have more options for treating a wide range of challenging cases. It accommodates easier advancement of devices with its 0.072' diameter, the largest inner diameter of any guiding catheter in the U.S., while providing better support and control at the same time. These features enhance treatment options for physicians, including the treatment of cases with complex lesions and those to be conducted using the radial approach," said Celine Martin, Worldwide President, Cordis Corporation.

The ADROITTM Catheter's innovative hybrid braid wire technology not only enables the production of a guide catheter with the largest lumen size on the U.S. market today, it also facilitates better control and back up support. In addition, the new innovative design incorporating a flexible distal segment and soft longer tip allows atraumatic placement and stability. The ADROITTM Guiding Catheter provides a wide range of shapes, including extra back-up shapes and radial specific shapes to support treatment needs of various coronary anatomies.

"Our vision at Cordis is to transform cardiovascular care, a field in which incredible progress has been made over the last decade, but one in which much more remains to be done. We are excited for the launch of our new ADROITTM Guiding Catheter as it complements our guide catheter portfolio with its technological and design advances. We will continue to deliver innovative solutions that save lives and improve the quality of life for people around the world," concluded Martin.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Periodontal treatment after heart rhythm ablation may reduce AFib recurrence